Clinical Trials Browser

Disease Progression × ibrutinib × Clear all

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression